GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Purchase Of Investment

PFE (Pfizer) Purchase Of Investment : $-10,313 Mil (TTM As of Dec. 2024)


View and export this data going back to 1951. Start your Free Trial

What is Pfizer Purchase Of Investment?

Pfizer's purchase of investment for the three months ended in Dec. 2024 was $-6,281 Mil. It means Pfizer spent $6,281 Mil on purchasing investments. Pfizer's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2024 was $-10,313 Mil.

Compared with last quarter ($-2,670 Mil in Sep. 2024 ), Pfizer spent more money on purchasing investments in Dec. 2024 ($-6,281 Mil).

Pfizer Purchase Of Investment Historical Data

The historical data trend for Pfizer's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Purchase Of Investment Chart

Pfizer Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14,402.00 -47,613.00 -38,780.00 -31,178.00 -10,313.00

Pfizer Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,228.00 -2,019.00 657.00 -2,670.00 -6,281.00

Pfizer Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10,313 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Pfizer's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Purchase Of Investment
Comparable Companies
GILD BMY AMGN MRK BIIB OGN AMRN SCLX MDCX MIRA LLY JNJ ABBV OCSE:NOVO B XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519
Traded in Other Exchanges
PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFEB:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Canada PFIZ34:Brazil PFE:Bulgaria PFE:Austria PFE:Argentina
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Website
https://www.pfizer.com
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
Jennifer B. Damico officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Ronald E Blaylock director
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff officer: Executive Vice President 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Payal Sahni officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler officer: Senior Vice President PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten officer: Senior Vice President 5 GIRALDA FARMS, MADISON NJ 07940
David M Denton officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao officer: Executive Vice President C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson officer: Executive Vice President PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie officer: Executive Vice President C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman officer: Senior Vice President 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang officer: Group President 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017